Log In
Print this Print this

WT1 ASCI (GSK2130579)

Also known as: 2130579

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionAntigen-specific cancer immunotherapeutic (ASCI) utilizing recombinant Wilms tumour suppressor gene (WT1)
Molecular Target Wilms tumor 1 (WT1)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today